Letters in Addition to Emailed Audit and Feedback in Refining Asthma Treatment in Primary Care

NCT05761873 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2026-01-22

No results posted yet for this study

Summary

Public Health England have estimated that 36,000 excess deaths occur each year due to UK air pollution. Respiratory inhalers produce 3% of NHS greenhouse gas production. The two main inhaler device categories are pressurised Metered Dose Inhalers (pMDIs) and Dry Powder Inhalers (DPIs). The chemical propellant in pMDIs is the majority cause of inhaler carbon footprint, with pMDIs having an 18 times higher carbon footprint than DPIs. The rates of asthma in the UK population are amongst the highest worldwide and its mortality rate remains amongst the worst in Europe.

A pre-existing Audit and Feedback (A\&F) quality improvement project (QIP) is being undertaken by NHS West Yorkshire Integrated Care Board (ICB) with the aim of improving asthma outcomes and reducing the environmental impact of inhalers in primary care. The A\&F being utilised here has been validated locally in two peer reviewed studies and is now standard practice in the region. There is convincing evidence that A\&F has a positive effect on enacting behaviour change, especially where behaviour change is related to prescribing with low baseline compliance with guidelines. However, the evidence base is poor on which design features of A\&F produce enhanced results. There is supporting evidence from local studies suggesting that posted paper A\&F may be more effective at producing behaviour change than emailed copies of A\&F alone.

This study seeks to randomise the primary care practices within the pre-arranged QIP, to receive either a paper and emailed A\&F report bimonthly for the duration of the study period, or to receive an emailed A\&F report alone. The primary outcome of the study would be a comparison of the number of 'low-global warming potential' inhalers prescribed as a percentage of the total prescribed inhalers from each intervention group.

Conditions

Interventions

OTHER

Provision of audit and feedback via email and paper

Provision of A\&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.

OTHER

Provision of audit and feedback via paper only

Provision of A\&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.

Sponsors & Collaborators

  • NHS West Yorkshire Integrated Care Board

    collaborator UNKNOWN
  • University of Leeds

    lead OTHER

Principal Investigators

  • Owen Thomas, MBBS · University of Leeds

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-24
Primary Completion
2024-05-17
Completion
2025-04-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05761873 on ClinicalTrials.gov